अApnaFunda
Menu

ARTEMIS MEDICARE SERVICES LTD (ARTEMISMED)

Health Services · Hospital/Nursing Management · figures to Nov '26

Quality scoreHow the business itself ranks against its sector peers on profitability, 3-year growth and leverage. 50 is the middle of the sector.57 / 100
Profitability 43Growth 66Balance sheet 61
Momentum scoreHow strong the recent trend is: 3-month price change, 12-month improvement in earnings and the rise in FII + DII holding, among companies above ₹500 cr.62 / 100
Price 60Earnings 64
Compare withAPOLLO HOSPITALS ENTERPRISES LMAX HEALTHCARE INSTITUTEASTER DM QUALITY CARE

Share price

Closing priceAdjusted for splits and bonus issues.

₹308.45 latest close · +18.7% over the last 90 sessions

₹250₹300₹350Jul 3Jul 29Aug 24Sep 17Oct 14Nov 9 ₹250₹300₹350Jul 3Sep 4Nov 9

₹308.45 month-end · +8.1% over 12 months

₹200₹250₹300₹350Nov '25Jan '26Apr '26Jun '26Sep '26Nov '26 ₹200₹250₹300₹350Nov '25May '26Nov '26

₹308.45 month-end · +79.7% over 3 years

₹200₹300Nov '23Jun '24Jan '25Sep '25Apr '26Nov '26 ₹200₹300Nov '23May '25Nov '26

₹308.45 month-end · +971.0% since Jan '20

₹0₹100₹200₹300Jan '20May '21Oct '22Feb '24Jul '25Nov '26 ₹0₹100₹200₹300Jan '20Jun '23Nov '26

52-week range ₹203.35 to ₹378.80 · 1-year volatility 37.9%

Was the rally earned?

+8%share price, 1 yearLower P/E held it back

Mostly yes, with a catch.

  • Per-share earnings added 17 points, but investors now pay less per rupee of profit (P/E 45.2x to 41.4x), which took 9 points back.
  • The share count rose 15%.
Net profit growth: +32 pts. Points of the price return explained by net profit growing (or shrinking).+32 ptsNet profit growthP/E change: −9 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−9 ptsP/E changeShare count change: −15 pts. Points of the price return explained by the share count changing. More shares count against the price.−15 ptsShare count changeShare price: +8%+8%Share priceNet profit growth: +32 pts. Points of the price return explained by net profit growing (or shrinking).+32ProfitP/E change: −9 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−9P/EShare count change: −15 pts. Points of the price return explained by the share count changing. More shares count against the price.−15SharesShare price: +8%+8%Share price
Net profit growth+32 ptsNet profit rose about 36%, which lifts the price.
P/E change-9 ptsThe P/E fell from 45.2x to 41.4x, which lowers the price.
Share count change-15 ptsShare count rose 15%, which lowers the price.
+80%share price, 3 yearsLower P/E held it back

Mostly yes, with a catch.

  • Per-share earnings added 129 points, but investors now pay less per rupee of profit (P/E 59.6x to 41.4x), which took 49 points back.
  • The share count rose 20%.
Net profit growth: +154 pts. Points of the price return explained by net profit growing (or shrinking).+154 ptsNet profit growthP/E change: −49 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−49 ptsP/E changeShare count change: −25 pts. Points of the price return explained by the share count changing. More shares count against the price.−25 ptsShare count changeShare price: +80%+80%Share priceNet profit growth: +154 pts. Points of the price return explained by net profit growing (or shrinking).+154ProfitP/E change: −49 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−49P/EShare count change: −25 pts. Points of the price return explained by the share count changing. More shares count against the price.−25SharesShare price: +80%+80%Share price
Net profit growth+154 ptsNet profit rose about 211%, which lifts the price.
P/E change-49 ptsThe P/E fell from 59.6x to 41.4x, which lowers the price.
Share count change-25 ptsShare count rose 20%, which lowers the price.
+814%share price, 5 yearsLower P/E held it back

Mostly yes, with a catch.

  • Per-share earnings added 1001 points, but investors now pay less per rupee of profit (P/E 68.9x to 41.4x), which took 187 points back.
  • The share count rose 29%.
Net profit growth: +1096 pts. Points of the price return explained by net profit growing (or shrinking).+1096 ptsNet profit growthP/E change: −187 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−187 ptsP/E changeShare count change: −95 pts. Points of the price return explained by the share count changing. More shares count against the price.−95 ptsShare count changeShare price: +814%+814%Share priceNet profit growth: +1096 pts. Points of the price return explained by net profit growing (or shrinking).+1096ProfitP/E change: −187 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−187P/EShare count change: −95 pts. Points of the price return explained by the share count changing. More shares count against the price.−95SharesShare price: +814%+814%Share price
Net profit growth+1096 ptsNet profit rose about 1867%, which lifts the price.
P/E change-187 ptsThe P/E fell from 68.9x to 41.4x, which lowers the price.
Share count change-95 ptsShare count rose 29%, which lowers the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with APOLLO HOSPITALS ENTERPRISES L

How rough has the ride been?

Maximum drawdown-56.8%recovered 2021-06
1-year volatility37.9%annualised
Beta vs sector index0.793-year daily, correlation 0.34
Volume spikes9last 90 sessions, 5x the 50-day median

Drawdown from peak

0%−20%−40%−60%202120222023202420252026−56.1% 0%−20%−40%−60%202120232025−56.1%
Largest drawdowns

-56.8% (2020-01 peak to 2020-03 low, recovered 2021-06)

-39.6% (2024-12 peak to 2026-03 low, recovered 2026-09)

-24.5% (2024-01 peak to 2024-03 low, recovered 2024-05)

Most recent volume spikes

2026-09-28: 7.3x the 50-day median, price +2.3% that day

2026-09-25: 68.1x the 50-day median, price +7.5% that day

2026-08-21: 5.4x the 50-day median, price +1.5% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

41.4xP/E todayWithin its usual range
Against its own history51st percentile
CheapestMedian 41.4xDearest

Usual range 14.3x to 76.3x since 2020-01.

Against Health Services41.4x vs 50.9x
This company
41.4x
Sector median
50.9x

19% below the Health Services median.

10.3x38.3x66.3x94.3xJan '20Jun '21Nov '22Apr '24Sep '25Nov '2610.3x38.3x66.3x94.3xJan '20May '22Sep '24Nov '26
P/E (this company)10th to 90th percentile of its own historyIts medianHealth Services median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Services median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Services median
How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Services is valued

Where does it rank among Health Services peers?

Each cell is the company's percentile rank among its Health Services peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

  • ROCE45th▼ 7 pts vs a year ago
  • Op. margin41st▲ 18 pts vs a year ago
  • Revenue growth33rd▲ 8 pts vs a year ago
  • EPS growth59th▼ 33 pts vs a year ago
  • Debt/equity ↓56th▲ 14 pts vs a year ago
  • Cash cycle ↓27th▼ 6 pts vs a year ago
  • P/E ↓63rd▼ 9 pts vs a year ago
  • 12M momentum66th▲ 38 pts vs a year ago

Rank history

ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26
Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Services sector page Watch it move against Health Services in the Observatory

What is the price implying?

~32%annual earnings growth implied by the priceBelow delivered growth

At normalised P/E (five-year average earnings) of 76.9x, a holder earning 12%/yr needs earnings to grow about 31.6%/yr for 10 years, then trade at 15x.

Delivered35.6%/yrEPS, last 8 fiscal years · 3-yr avg to 3-yr avg
Gap−4.0 ptsimplied minus delivered
Rank611thmost demanding of 856

Over time

Implied growth by month (solid) and delivered growth (dashed).

0%21%42% Jan 2020Nov 2026 0%21%42% Jan 2020Nov 2026

Change the assumptions

Exit P/E / return11%12%13%
12x33.3%34.5%35.7%
15x30.4%31.6%32.7%
20x26.8%27.9%29.0%

Drag a slider to test other assumptions

Implied: 31.6%/yr

Looking back

  • Jan 2020Price implied 20%/yr; EPS has since grown 23%/yr (7.0 yrs)
  • Jan 2021Price implied 11%/yr; EPS has since grown 28%/yr (6.0 yrs)
  • Jan 2022Price implied 23%/yr; EPS has since grown 70%/yr (5.0 yrs)

Past comparisons cover only companies listed today (survivorship bias) and say nothing about future outcomes.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect. How this is calculated and the market-wide lists.

What prices imply across Health Services The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov
₹308.45
P/E
41.4x
ROCE
15.0%
Market Cap
₹4887 cr
Revenue (TTM)
₹1113 cr
P/S
4.4x
P/B
5.2x
ROE
12.6%
Operating Margin
20.0%
Debt / Equity
0.3x
Promoter Holding
58.4%
12M Momentum
8.1%

52-week range

₹203.35₹378.80
60% of the way from its 52-week low to its high

Price risk

1Y volatility
37.9%
Beta vs sector
1-year daily
0.85

Balance sheet & cash

Interest cover
operating profit ÷ interest
6.9x
Cash from profit, 3Y
operating cash flow ÷ net profit
1.69x
Share count, 1Y
+14.3%

Are profits backed by cash?

4 of 6checks within range2 near a threshold
Other income reliance16%Near threshold

Other income as a share of pre-tax profit (trailing twelve months): 16.4%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate25%Within range

Median quarterly effective tax rate over about 2.5 years: 25.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion1.69xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 1.69x (cash from operations ₹397 cr, net profit ₹235 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow3 of 5 yrsNear threshold

Fiscal years with positive free cash flow in the last 5: 3. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+1 daysWithin range

Debtor days are above the median of the previous three fiscal years by 1 days (40 vs 39). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress4% of fixed assetsWithin range

Capital work-in-progress is 4% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days—Not enough data

Not enough reported data to compute this.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

  • Over 2 years, FIIs added 12.2 pts; promoters trimmed 9.6 pts.
  • The number of shareholders rose from 22,375 to 36,335 (+62%) between Dec 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupDec '23Jun '26Change
Promoters68.0%58.4%-9.6 pts
FIIs0.1%12.3%+12.2 pts
DIIs2.0%2.4%+0.4 pts
Public and others22.7%20.8%-2.0 pts

Number of shareholders

36,335shareholders+62% since Dec '23
20k25k31k36k Dec '23Jun '24Dec '24Jun '25Dec '25Jun '26
Dec '23: 22,375
Mar '24: 19,993
Jun '24: 19,795
Sep '24: 26,054
Dec '24: 27,004
Mar '25: 28,397
Jun '25: 31,614
Sep '25: 33,559
Dec '25: 31,602
Mar '26: 32,044
Jun '26: 36,335
 20k25k31k36k Dec '23Dec '24Dec '25Jun '26
Dec '23: 22,375
Mar '24: 19,993
Jun '24: 19,795
Sep '24: 26,054
Dec '24: 27,004
Mar '25: 28,397
Jun '25: 31,614
Sep '25: 33,559
Dec '25: 31,602
Mar '26: 32,044
Jun '26: 36,335

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

+1.8%typical 12-month return vs the marketNot meaningfully different from the base rate
  • We found 50 past situations where a non-financial company looked like ARTEMIS MEDICARE SERVICES LTD today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −28% to +28% vs the market, against −4% for all non-financial companies in the same months.
  • The gap against the base rate (+5.5%, 80% range −6.4% to +15.9%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

−100%−50%0%+50%+100%
THEMISMED · Dec 2024: −63.8% vs market
ASIANTILES · Jan 2021: −63.0% vs market
MOTISONS · Jan 2025: −54.4% vs market
EPL · Nov 2020: −46.2% vs market
RKFORGE · Oct 2024: −42.5% vs market
VRLLOG · Jan 2020: −41.4% vs market
BOROLTD · Jan 2025: −39.0% vs market
CARYSIL · Mar 2024: −38.7% vs market
ASTEC · Sep 2022: −38.4% vs market
SYMPHONY · Sep 2024: −37.5% vs market
INDOCO · Aug 2021: −30.3% vs market
SULA · Dec 2023: −28.9% vs market
RESPONIND · Jun 2024: −28.1% vs market
GUFICBIO · Feb 2025: −27.5% vs market
SOMANYCERA · Feb 2022: −26.3% vs market
GODREJAGRO · Apr 2020: −23.0% vs market
JYOTHYLAB · Apr 2020: −21.1% vs market
HUHTAMAKI · Jul 2020: −20.6% vs market
5PAISA · Oct 2023: −17.0% vs market
HSCL · Jan 2025: −12.0% vs market
BAJAJELEC · Jul 2021: −8.6% vs market
GREENLAM · Feb 2022: −6.7% vs market
RATNAMANI · Mar 2023: −5.1% vs market
JAMNAAUTO · Apr 2022: −3.8% vs market
SUPRAJIT · Mar 2021: +0.5% vs market
CERA · Sep 2021: +3.0% vs market
ANURAS · Jul 2022: +6.7% vs market
THEJO · Sep 2023: +8.1% vs market
MOLDTKPAC · Feb 2020: +14.9% vs market
BECTORFOOD · Apr 2024: +14.9% vs market
MIDHANI · Sep 2025: +15.4% vs market
AEGISLOG · Jan 2020: +15.5% vs market
TEGA · Mar 2025: +15.7% vs market
METROPOLIS · Oct 2025: +17.1% vs market
RADICO · Apr 2020: +20.8% vs market
ASTRAMICRO · Jan 2025: +24.7% vs market
KNRCON · May 2020: +25.7% vs market
ETHOSLTD · Oct 2023: +28.2% vs market
IPCALAB · Aug 2025: +32.5% vs market
SUNDRMFAST · Jul 2022: +33.2% vs market
JASH · May 2023: +43.8% vs market
CCL · Jun 2022: +44.3% vs market
NEWGEN · Jan 2021: +44.5% vs market
CRAFTSMAN · Nov 2022: +45.1% vs market
ELGIEQUIP · Jul 2021: +57.1% vs market
THYROCARE · Aug 2024: +59.2% vs market
CENTURYPLY · Feb 2021: +61.5% vs market
KPITTECH · Sep 2021: +92.4% vs market
SANSERA · Oct 2025: +187.1% vs market
FLUOROCHEM · May 2021: +222.6% vs market
Similar setups +1.8%All companies −3.7%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 2 beyond the range shown, drawn at the edge

Similar setups' median
+1.8%
All companies' median
−3.7%
Beat the market
52% vs 46%

50 past situations · 50 companies · 37 months · 2020–2025

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
SUPRAJIT
Producer Manufacturing		 Mar 2021 37x15% +145%−8% +1%
RADICO
Consumer Non-Durables		 Apr 2020 20x19% −17%−33% +21%
CENTURYPLY
Producer Manufacturing		 Feb 2021 45x14% +95%−4% +62%
RESPONIND
Non-Energy Minerals		 Jun 2024 53x15% +98%−9% −28%
ELGIEQUIP
Producer Manufacturing		 Jul 2021 68x13% +175%−3% +57%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
GUFICBIO
Health Technology		 Feb 2025 39x— +5%−32% −28%
ASTRAMICRO
Electronic Technology		 Jan 2025 54x19% +29%−27% +25%
SULA
Process Industries		 Dec 2023 50x20% +50%−5% −29%
How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: P/E, 12-month momentum and drawdown from 12-month high. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to ARTEMIS MEDICARE SERVICES LTD. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

INNOVA CAPTABINNOVACAP
Health Technology
74%similar
ROCEP/E
VADILAL INDUSTRIESVADILALIND
Consumer Non-Durables
66%similar
market capdebt/equity
PICCADILY AGRO INDUSTRIESPICCADIL
Process Industries
63%similar
P/Erevenue
PITTI ENGINEERINGPITTIENG
Producer Manufacturing
62%similar
ROCEmarket cap
TALBROS AUTOMOTIVE COMPONENTSTALBROAUTO
Producer Manufacturing
62%similar
promoter holdingrevenue
YATHARTH HOSPITAL TRAUMAYATHARTH
Health Services
66%similar
volatilityrevenue
JUPITER LIFE LINE HOSP.JLHL
Health Services
60%similar
ROCEoperating margin
VIJAYA DIAGNOSTIC CENTREVIJAYA
Health Services
58%similar
EPS growthrevenue

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Apr '23

  1. SepPriceRegained the 2024-12 peak, 6 months after the low.
  2. SepPriceVolume reached 68.1x its 50-day median on 2026-09-25; price +7.5% that day.
  3. JunPeer rankMoved into the 3rd quartile of Health Services on operating margin (from the bottom quartile).
  4. JunSharesShare count is up 14.3% over 12 months.
  5. MayPriceVolume reached 6.9x its 50-day median on 2026-05-11; price +5.8% that day.
  6. MarPromoterPromoter holding fell 8.1 pts to 58.4%.
  7. MarInstitutionsFII + DII holding rose 10.7 pts over 1 quarter to 15.4%.
  8. MarPriceFell 40% from the Dec 2024 peak to the Mar 2026 low.
Show 22 earlier events
  1. MarPeer rankSlipped to the 2nd quartile of Health Services on EPS growth (from the top quartile).
  2. FebPriceVolume reached 5.8x its 50-day median on 2026-02-03; price -9.2% that day.
  3. JanDebtDebt / equity halved over 12 months to 0.35x.
  4. DecPeer rankSlipped to the 3rd quartile of Health Services on ROCE (from the 2nd quartile).
  5. NovPriceVolume reached 16.6x its 50-day median on 2025-11-12; price +6.8% that day.
  6. SepPeer rankSlipped to the bottom quartile of Health Services on operating margin (from the 3rd quartile).
  7. SepPriceVolume reached 6.7x its 50-day median on 2025-09-01; price +2.9% that day.
  8. JunPeer rankMoved into the 2nd quartile of Health Services on ROCE (from the 3rd quartile).
  9. JunDebtDebt / equity halved over 12 months to 0.35x.
  10. MayPriceVolume reached 5.4x its 50-day median on 2025-05-27; price +3.4% that day.
  11. DecPeer rankMoved into the 3rd quartile of Health Services on operating margin (from the bottom quartile).
  12. NovPriceVolume reached 23.3x its 50-day median on 2024-11-21; price +10.7% that day.
  13. AugValuationP/E crossed above the 90th percentile of its own history to date (79.0x).
  14. JulPriceVolume reached 32.1x its 50-day median on 2024-07-11; price +16.1% that day.
  15. JunResultsRevenue (TTM) reached a new high of ₹879 cr.
  16. JunSharesShare count is up 7.7% over 12 months.
  17. DecPriceVolume reached 5.6x its 50-day median on 2023-12-19; price +4.5% that day.
  18. SepPriceVolume reached 8.6x its 50-day median on 2023-09-06; price +11.7% that day.
  19. JunResultsRevenue (TTM) reached a new high of ₹737 cr.
  20. JunPeer rankSlipped to the 2nd quartile of Health Services on EPS growth (from the top quartile).
  21. JunDividendStarted paying a dividend (payout 16% of profit).
  22. AprPriceVolume reached 17.2x its 50-day median on 2023-04-27; price +5.8% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history83 months · 2020-01 to 2026-11
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-1141.4x₹1113 cr12.6%15.0%0.3x
2026-1039.4x₹1113 cr12.1%15.0%0.3x
2026-0946.4x₹1113 cr12.1%15.0%0.3x
2026-0845.4x₹1081 cr11.0%15.0%0.3x
2026-0742.6x₹1081 cr11.0%15.0%0.3x
2026-0637.9x₹1081 cr11.0%15.0%0.3x
2026-0540.4x₹1042 cr11.5%15.0%0.3x
2026-0436.1x₹1042 cr11.5%15.0%0.3x
2026-0330.4x₹1042 cr11.5%15.0%0.3x
2026-0235.0x₹1002 cr11.3%15.0%0.3x
2026-0136.1x₹1002 cr11.3%15.0%0.3x
2025-1239.5x₹1002 cr11.3%15.0%0.3x
2025-1145.2x₹968 cr10.4%15.0%0.3x
2025-1039.2x₹968 cr10.4%15.0%0.3x
2025-0937.1x₹968 cr10.4%15.0%0.3x
2025-0836.4x₹936 cr9.9%15.0%0.3x
2025-0739.8x₹936 cr9.9%15.0%0.3x
2025-0642.3x₹936 cr9.9%15.0%0.3x
2025-0551.9x₹921 cr16.5%14.0%0.7x
2025-0447.0x₹921 cr16.5%14.0%0.7x
2025-0350.8x₹921 cr16.5%14.0%0.7x
2025-0249.0x₹908 cr14.5%14.0%0.7x
2025-0166.8x₹908 cr14.5%14.0%0.7x
2024-1266.6x₹908 cr14.5%14.0%0.7x
2024-1180.0x₹892 cr12.7%14.0%0.7x
2024-1068.2x₹892 cr12.7%14.0%0.7x
2024-0969.2x₹892 cr12.7%14.0%0.7x
2024-0879.0x₹879 cr10.9%14.0%0.7x
2024-0772.9x₹879 cr10.9%14.0%0.7x
2024-0649.0x₹879 cr10.9%14.0%0.7x
2024-0560.6x₹737 cr9.4%11.0%0.7x
2024-0463.3x₹737 cr9.4%11.0%0.7x
2024-0359.0x₹737 cr9.4%11.0%0.7x
2024-0259.1x₹737 cr9.4%11.0%0.7x
2024-0164.3x₹737 cr9.4%11.0%0.7x
2023-1262.6x₹737 cr9.4%11.0%0.7x
2023-1159.6x₹737 cr9.4%11.0%0.7x
2023-1053.4x₹737 cr9.4%11.0%0.7x
2023-0955.1x₹737 cr9.4%11.0%0.7x
2023-0843.6x₹737 cr9.4%11.0%0.7x
2023-0744.8x₹737 cr9.4%11.0%0.7x
2023-0643.5x₹737 cr9.4%11.0%0.7x
2023-0535.7x₹555 cr8.6%10.0%0.6x
2023-0433.0x₹555 cr8.6%10.0%0.6x
2023-0328.3x₹555 cr8.6%10.0%0.6x
2023-0227.2x₹555 cr8.6%10.0%0.6x
2023-0129.3x₹555 cr8.6%10.0%0.6x
2022-1231.7x₹555 cr8.6%10.0%0.6x
2022-1133.0x₹555 cr8.6%10.0%0.6x
2022-1029.7x₹555 cr8.6%10.0%0.6x
2022-0925.4x₹555 cr8.6%10.0%0.6x
2022-0826.2x₹555 cr8.6%10.0%0.6x
2022-0722.8x₹555 cr8.6%10.0%0.6x
2022-0617.4x₹555 cr8.6%10.0%0.6x
2022-0585.5x₹408 cr1.9%4.0%0.5x
2022-0490.9x₹408 cr1.9%4.0%0.5x
2022-0393.7x₹408 cr1.9%4.0%0.5x
2022-0279.8x₹408 cr1.9%4.0%0.5x
2022-0194.3x₹408 cr1.9%4.0%0.5x
2021-1285.2x₹408 cr1.9%4.0%0.5x
2021-1168.9x₹408 cr1.9%4.0%0.5x
2021-1069.7x₹408 cr1.9%4.0%0.5x
2021-0972.4x₹408 cr1.9%4.0%0.5x
2021-0870.6x₹408 cr1.9%4.0%0.5x
2021-0777.1x₹408 cr1.9%4.0%0.5x
2021-0666.5x₹408 cr1.9%4.0%0.5x
2021-0518.4x₹565 cr6.1%10.0%0.4x
2021-0412.8x₹565 cr6.1%10.0%0.4x
2021-0314.8x₹565 cr6.1%10.0%0.4x
2021-0215.5x₹565 cr6.1%10.0%0.4x
2021-0114.1x₹565 cr6.1%10.0%0.4x
2020-1215.1x₹565 cr6.1%10.0%0.4x
2020-1110.9x₹565 cr6.1%10.0%0.4x
2020-1011.0x₹565 cr6.1%10.0%0.4x
2020-0910.3x₹565 cr6.1%10.0%0.4x
2020-0810.8x₹565 cr6.1%10.0%0.4x
2020-0711.5x₹565 cr6.1%10.0%0.4x
2020-0612.1x₹565 cr6.1%10.0%0.4x
2020-0516.1x₹547 cr6.8%—0.4x
2020-0416.5x₹547 cr6.8%—0.4x
2020-0314.1x₹547 cr6.8%—0.4x
2020-0221.8x₹547 cr6.8%—0.4x
2020-0129.7x₹547 cr6.8%—0.4x

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback